Company / Current Liabilities
SAB Biotherapeutics, Inc. Current Liabilities History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$10.7M
FY2025
5-year range
$8.0M / $26.5M
FY2021-FY2025
Trend
+33.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities returned to growth in FY2025 after 2 years of decline, reaching $11M.
Based on SEC 10-K filings.
$11M in FY2025 with a 3-year CAGR of -26.1%.
Remained stable around $11M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -26.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -26.1%, indicating a declining trend.
- In FY2025, current liabilities increased 33.9% year-over-year.
- Peak current liabilities was recorded in FY2022.
- Lowest current liabilities in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.31 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.7M | +33.9% |
| FY2024 | $8.0M | -26.2% |
| FY2023 | $10.8M | -59.1% |
| FY2022 | $26.5M | +139.2% |
| FY2021 | $11.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026